Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Immunoblastic Lymphadenopathy 1

Interventions

Cyclophosphamide 11Doxorubicin 9Vincristine 8Methotrexate 6nelarabine 5Prednisone 5Peripheral Blood Stem Cell Transplantation 5Leucovorin 5Cytarabine 5tanespimycin 4merphos 4fludarabine phosphate 4dexamethasone acetate 4dexamethasone 21-phosphate 4auricularum 4Magnetic Resonance Spectroscopy 4Gemcitabine 4Etoposide 4Dexamethasone 4Cyclosporine 4Calcium Dobesilate 4Bortezomib 4prednylidene 3pegaspargase 3deltacortene 3azathiopurine 3Vorinostat 3Thioguanine 3Radiotherapy 3Pharmacogenomic Testing 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × Abatacept × Clear all
NCT07388563 2026-05-08

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1 Suspended
20 enrolled
LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡